MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of MYO-029. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of MYO-029. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of MYO-029. |
| Estrone | Estrone may increase the thrombogenic activities of MYO-029. |
| Estradiol | Estradiol may increase the thrombogenic activities of MYO-029. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of MYO-029. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of MYO-029. |
| Mestranol | Mestranol may increase the thrombogenic activities of MYO-029. |
| Estriol | Estriol may increase the thrombogenic activities of MYO-029. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of MYO-029. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of MYO-029. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of MYO-029. |
| Tibolone | Tibolone may increase the thrombogenic activities of MYO-029. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of MYO-029. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of MYO-029. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of MYO-029. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of MYO-029. |
| Zeranol | Zeranol may increase the thrombogenic activities of MYO-029. |
| Equol | Equol may increase the thrombogenic activities of MYO-029. |
| Promestriene | Promestriene may increase the thrombogenic activities of MYO-029. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of MYO-029. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of MYO-029. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of MYO-029. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of MYO-029. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of MYO-029. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of MYO-029. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of MYO-029. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of MYO-029. |
| Formononetin | Formononetin may increase the thrombogenic activities of MYO-029. |
| Estetrol | Estetrol may increase the thrombogenic activities of MYO-029. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with MYO-029. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with MYO-029. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with MYO-029. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with MYO-029. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with MYO-029. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with MYO-029. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with MYO-029. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with MYO-029. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with MYO-029. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with MYO-029. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with MYO-029. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with MYO-029. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with MYO-029. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with MYO-029. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with MYO-029. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with MYO-029. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with MYO-029. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with MYO-029. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with MYO-029. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with MYO-029. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with MYO-029. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with MYO-029. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with MYO-029. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with MYO-029. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with MYO-029. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with MYO-029. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with MYO-029. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with MYO-029. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with MYO-029. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with MYO-029. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with MYO-029. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with MYO-029. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with MYO-029. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with MYO-029. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with MYO-029. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with MYO-029. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with MYO-029. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with MYO-029. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with MYO-029. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with MYO-029. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with MYO-029. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with MYO-029. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with MYO-029. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with MYO-029. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with MYO-029. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with MYO-029. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with MYO-029. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with MYO-029. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with MYO-029. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with MYO-029. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with MYO-029. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with MYO-029. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with MYO-029. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with MYO-029. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with MYO-029. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with MYO-029. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with MYO-029. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with MYO-029. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when MYO-029 is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when MYO-029 is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when MYO-029 is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when MYO-029 is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when MYO-029 is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Canakinumab. |